3 Years of Tralokinumab Treatment Provides Long Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Modera Te to Severe Atopic Dermatitis. J of Skin 2023, 7 (2), s142. https://doi.org/10.25251/skin.7.supp.142.